---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-264392"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-06-09T22:11:53+00:00"
generated_at: "2026-06-10T10:10:02.102930+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Director Brian Thomas resigns from Metagenomi board; shareholders re-elect Eckhardt, Bjerkholt and ratify PwC as auditor

## Summary
- Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.
- Juergen Eckhardt and Eric Bjerkholt elected as Class II directors to serve until 2029 annual meeting.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 18,483,295 votes for, 51,847 against.
- Quorum of 19,116,207 shares present out of 37,647,057 outstanding at the June 9, 2026 annual meeting.

## SEC filing metadata
- accession: 0001193125-26-264392
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-06-09T22:11:53+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-264392
- JSON: https://secwatch.observer/filing/0001193125-26-264392.json
- Plain text: https://secwatch.observer/filing/0001193125-26-264392.txt

## Key facts
- Executive change
  Brian C. Thomas resigned as director at Metagenomi Therapeutics, Inc..
  - Action: resigned
  source text: On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm
- Shareholder Votes
  Metagenomi Therapeutics, Inc. shareholders approved Election of Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II Directors at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 1 - Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until the Company’s 2029 annual meeting of stockholders, and until their respective successor shall have been duly elected and qualified, or until their earlier death, resignation or removal, based on the following votes: Class II Director Nominee For Withheld Broker Non-Votes Juergen Eckhardt, M.D., M.B.A. 7,296,718 1,436,882 10,382,607 Eric Bjerkholt, M.B.A. 8,251,289 482,311 10,382,607
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm
- Shareholder Votes
  Metagenomi Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 18,483,295 51,847 581,065
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.